In addition, 66.7% of mice treated with DEXP&A&N in combination with Flt3L were cured of primary tumors on day 28 and remained tumor-free 14 days after tumor re-challenge (Fig. 6b, c). This evidence concerns the gene FLT3LG and neoplasm.